Mukai, Hirofumi
Shimizu, Chikako
Masuda, Norikazu
Ohtani, Shoichiro
Ohno, Shinji
Takahashi, Masato
Yamamoto, Yutaka
Nishimura, Reiki
Sato, Nobuaki
Ohsumi, Shozo
Iwata, Hiroji
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Nagasawa, Takashi
Umeyama, Yoshiko
Lu, Dongrui R.
Toi, Masakazu
Funding for this research was provided by:
Pfizer (None)
Article History
Received: 12 June 2018
Accepted: 3 October 2018
First Online: 4 December 2018
Compliance with ethical standards
:
: H. Mukai, C. Shimizu, M. Takahashi, R. Nishimura, and S. Ohsumi have no conflicts of interest to report. N. Masuda has received honoraria from Chugai, AstraZeneca, Pfizer, and Takeda and research funding from Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli Lilly, and Daiichi Sankyo. S. Ohtani has received honoraria from Chugai and Eisai. S. Ohno has received honoraria from Chugai, AstraZeneca, Eisai, Taiho, Novartis, Pfizer, Kyowa-Hakko Kirin, and Sanofi; and research funding from Taiho, Chugai, and Daiichi Sankyo. Y. Yamamoto has received honoraria from Pfizer. N. Sato has received honoraria from Chugai, AstraZeneca, Eisai, Pfizer, and Taiho. H. Iwata has received honoraria and research funding from Pfizer and AstraZeneca, and fees for promotional materials from AstraZeneca. M. Toi has received honoraria from Novartis, MSD, Takeda, AstraZeneca, Taiho, Chugai, Pfizer, Eisai, Eli Lilly, Kyowa-Hakko Kirin, and Genomic Health Institute; research funding from Novartis, AstraZeneca, Taiho, Chugai, Pfizer, and Eli Lilly; served as a consultant/independent contractor for Kyowa-Hakko Kirin and on an advisory board for Genomic Health Institute. S. Hashigaki, Y. Muramatsu, and T. Nagasawa are employees of Pfizer; D. Lu, Y. Mori, and Y. Umeyama are employees of and stockholders in Pfizer.